ArticleTransplantation2026
Untargeted Plasma Proteomic Signatures and Late Graft Failure in Kidney Transplant Recipients.
Article in Transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundLong-term kidney graft monitoring still relies on delayed clinical indicators such as eGFR and proteinuria, which change only after substantial injury. To investigate biological processes not captured by standard metrics, we hypothesized that plasma proteomics could identify biomarkers and reveal the pathways underlying the pathological process, thereby providing independent prognostic value for late graft failure.
methodsIn this retrospective matched case-control study, we analyzed pre-event plasma samples from 29 kidney transplant recipients who later experienced late, death-censored graft failure (DCGF; occurring ≥1 y posttransplant) and 49 matched recipients without DCGF from the TransplantLines Biobank. We quantified 800 proteins by label-free liquid chromatography with tandem spectrometry, followed by differential expression analysis and survival-related feature selection. Independent survival markers were evaluated using random survival forests. Biological context was analyzed via STRING network and enrichment analyses.
resultsThe cohort (n = 78) had a baseline age of 49.8 ± 14.1 y and estimated glomerular filtration rate of 36.9 ± 13.2 mL/min/1.73 m 2 . Median time between transplantation and baseline was 2.7 (0.7-7.8) y with 4.6 (2.1-5.8) y of follow-up. Seventeen proteins differed at baseline between cases and controls, including HLA-A and lipopolysaccharide-binding protein. Feature selection identified a 113-protein signature enriched in lipid metabolism, coagulation, and immunity. This signature provided significant prognostic value independent of clinical parameters such as estimated glomerular filtration rate and proteinuria (C-index 0.878 versus 0.851, P < 0.001). After accounting for confounders, apolipoprotein L1 and C1 were the most prominent.
conclusionsProteomic profiling may provide novel biological insights into the pathogenesis of DCGF and may complement existing clinical metrics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.